rch and development 9,1716,93833,55727,448Selling, general and administrative 21,55712,02571,15548,083Advertising and promotion4,22859114,3001,944Amortization of intangible assets3,4831,47910,5056,389Acquisition costs111—3,583—Restructuring charge30,741—31,348—Other operating expenses9541241,4591,080Total operating expenses70,24521,157165,90784,944Income (loss) from operations(8,092)17,23350,84663,616Interest (expense) income and other, net(263)1(3,555)428Income (loss) before income tax provision(8,355)17,23447,29164,044Income tax provision (benefit) (2,209)6,19519,39123,454Net income (loss)
$
(6,146)$
11,039$
27,900$
40,590Basic earnings (loss) per share
$
(0.18)$
0.33$
0.84$
1.22Diluted earnings (loss) per share
$
(0.18)$
0.33$
0.83$
1.22Shares used in computing basic earnings (loss) per share33,49033,25333,40433,207Shares used in computing diluted earnings (loss) per share33,49033,42433,57533,363Unaudited Condensed Consolidated Balance Sheets DataOctober 31,October 31, 20102009Assets:Cash and cash equivalents
$63,746$
141,063Short-term investments—7,301Accounts receivable, net69,56944,304Inventories, net93,976116,179Other current assets6,6955,240Property, plant and equipment, net221,770252,279Deferred tax asset9,42924,303Long-term investments4,9554,495Goodwill, intangibles and other long-term assets, net328,02194,653Total assets
$798,161$
689,817Liabilities and stockholders' equity:Accounts payable and accrued expenses
$52,517$
31,365Notes payable and other long-term obligations6,938810Deferred tax liability58,97810,091Deferred revenue8,74511,407Stockholders' equity670,983636,144Total liabilities and stockholders' equity
$798,161$
689,817Unaudited Condensed Consolidated Cash Flow DataYear ended October 31,20102009Operating activities:Net income
$
2
'/>"/>
SOURCE Martek Biosciences Corporation Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 Related biology technology :1.
Martek to Present at Upcoming Citi Small / Mid Cap Conference2.
Martek to Present at Upcoming UBS Conference3.
Martek Announces Third Quarter FY 2010 Financial Results4.
Martek Announces Fourth Quarter and FY 2009 Financial Results5.
Martek Signs Sole-Source Supply Agreement with Fonterra6.
Martek to Announce Fourth Quarter and Fiscal Year 2009 Results7.
Martek Announces Addition to Its Board of Directors8.
Martek to Present at Two Upcoming Investor Conferences9.
Martek Announces Settlement of Patent Dispute with Capsugel France10.
Federal Circuit Rules in Marteks Favor in Appeal of Patent Infringement Case11.
Martek Signs Sole-Source Supply Agreement with Milk Powder Solutions